Development and results of an integrated platform based on emerging technologies for the evaluation of risk factors, diagnosis, treatment, prognosis and geolocation in Pandemic Covid-19 by SARS-Cov-2

ABSTRACT

An explanatory longitudinal and prospective experimental cutting study was conducted with deliberate intervention, where a platform based on emerging technologies for epidemiological and clinical approach to the Covid 19 pandemic was developed in terms of risk factors, diagnosis, treatment, prognosis and geolocation. The diagnostic efficacy of Covid 19 disease was demonstrated through evaluation by this application with a sensitivity of 56% and a specificity of 95%, with a positive likelihood ratio of 12. With regard to the assessment of the risk status in the population, there was a sensitivity of 18% with a specificity of 87%. While the positive likelihood rate was 1.5. The determination of ELISA Immunoassay Antibodies (IgM and IgG) for SARS-Cov-2 was positive in 86% of confirmed cases, the determination of antigens (Rapid Tests) showed efficacy for ruling out infection in 73.3% of patients studied. RT-qPCR was the confirming method of molecular diagnosis of virus infection in 90% of confirmed cases. 86% of confirmed cases required treatment and poor prognostic factors were detected in 18.6% of patients evaluated. There were no deaths for Covid 19. The relative risk of complications attributable to this coronavirus was twice as high before evaluation through the Emerging Technologies-based platform. 100% of the patients included were geolocated. The platform showed efficiency and effectiveness for the integral management of the Covid 19 Pandemic.